No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence
Protagenic Therapeutics' Reports Safety Data From Single Dose Portion Of Phase 1 Trial Involving PT00114
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.